Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Diagnostics (Basel, Switzerland)|May 13, 2026
Uric Acid-Driven Biomarkers and Clinical Outcomes in Metastatic Pancreatic Cancer: A Multicenter Real-World Cohort StudyAhmet Unlu, Asim Armagan Aydin, Mehmet Nuri Baser, et al.Diagnostics (Basel, Switzerland)|July 15, 2026
Prognostic Impact of Immune-Inflammatory and Nutritional Indices in Metastatic Hormone-Sensitive Prostate CancerMehmet Nuri Baser, Ahmet Baklaci, Ahmet Unlu, et al.Current Oncology (Toronto, Ont.)|October 28, 2025
Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot StudyAli Erhan Eren, Asim Armagan Aydin, Eren Erdi Aksaray, et al.Journal of Clinical Medicine|July 28, 2026
Platelet-to-Albumin Ratio and Clinical Outcomes in IDH-Wildtype Grade 4 Diffuse GliomaOzan Deniz Guven, Asim Armagan Aydin, Ahmet Unlu, et al.Cureus|November 11, 2024
Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Advanced Pancreatic CancerAsim Armagan Aydin, Erkan Kayikcioglu, Ahmet Unlu, et al.Expert Review of Anticancer Therapy|August 29, 2025
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocolAsim Armagan Aydin, Ahmet Unlu, Neslihan Atabek, et al.Medicina (Kaunas, Lithuania)|May 27, 2026
Preoperative Lactate Dehydrogenase-to-Albumin Ratio as a Tumor-Host Biomarker of Early Recurrence and Survival in Resected Pulmonary Neuroendocrine Carcinomas: A Multicenter Observational Cohort StudyHacer Boztepe Yesilcay, Asim Armagan Aydin, Ahmet Baklaci, et al.Journal of Clinical Medicine|May 13, 2026
Pretreatment Lactate Dehydrogenase-to-Albumin Ratio and Clinical Outcomes in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World StudyAhmet Unlu, Asim Armagan Aydin, Esra Sazimet Kars, et al.Cancers|February 13, 2026
Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)Sercan On, Selin Cebeci, Zeynep Hande Turna, et al.International Journal of Cancer|October 28, 2025
Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world studySalih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel, et al.Pageof 3